This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Neuralstem CSO, Dr. Karl Johe, To Speak At 6th Neurodegenerative Conditions Research And Development Conference

Stocks in this article: CUR

ROCKVILLE, Md., Sept. 11, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that Karl Johe, PhD, will give an update on the NSI-189 ongoing clinical trial in major depressive disorder (MDD) at the 6 th Neurodegenerative Conditions Research and Development conference, September 13-14, in San Francisco, CA ( http://www.gtcbio.com/index.php?option=com_conference&file=speaker&cn=5th%20Neurodegenerative&cid=37). NSI-189 is the lead compound in Neuralstem's neurogenic small molecule platform, which seeks to develop oral drugs for CNS conditions, such as depression and chronic traumatic encephalopathy (CTE). Dr. Johe's talk, " Novel Neurogenic Drugs Targeting Hippocampal Degeneration," will take place on September 14 th at 11:10 AM PDT. Dr. Johe is the Chairman and Chief Scientific Officer of Neuralstem.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

"We are pleased with the progress of NSI-189 in the trial for major depression, which has progressed from healthy volunteers to MDD patients," said Dr. Johe. "Evident from recent findings in Alzheimer's disease research, neurodegeneration occurs two decades before the first symptom is apparent. We should consider MDD as a neurodegenerative disease. By recruiting the endogenous neural stem cells in the patient's brain, NSI-189, a one a day oral drug, aims to counter the chronic neurodegeneration, stimulate the generation of new neurons in hippocampus, and increase hippocampal volume. The drug should also work on other diseases such as Alzheimer's dementia that involve progressive neurodegeneration and eventual atrophy of hippocampus."

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia and chronic stroke. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs